Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema THERANEXUS

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
29.04.THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT416Lyon, France - 29 April 2024 - 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31 December...
► Artikel lesen
23.04.THERANEXUS: Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide226Lyon, April 23rd, 2024 Sponsors of the PickASO project, a winner of the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030, Theranexus, Diverchim and Inserm's...
► Artikel lesen
18.04.THERANEXUS: Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1293Stabilization of motor symptom progression in young adult patients suffering from juvenile Batten disease (CLN3) after 18 months of treatment Lyon, France - Austin, Texas, United States - 18 April...
► Artikel lesen
11.03.THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN240Lyon, France - 11 March - 8:00 am CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces the appointment of Mathieu Charvériat...
► Artikel lesen
14.02.THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS302Lyon, France - 14 February - 6pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as at...
► Artikel lesen